MRK trims its 2025 sales range but lifts the lower end of its EPS outlook. Keytruda, Animal Health and new drugs are expected ...

The recent portfolio rebalance increased FDL's risk and volatility, with 55% concentration in its top 10 holdings. Read why I ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

These two reliable and high-yielding dividend payers from the healthcare sector should be on your buy list today.

A Newsweek report reveals America's Most Responsible Companies for 2025, with a New Jersey-based company earning the top spot ...

Merck MRK stock has declined 4% since it announced second-quarter results on July 29 before market open. While the company’s ...

MRK scores an A+ grade for Profitability, aided by high gross and EBITDA margins of 78% and 46%, respectively. Moreover, it ...

This podcast was recorded on July 21, 2025. Tim Beyers: Is it time to buy biotech? You're listening to Motley Fool Money.

Reports second quarter revenues of $0.1 billion, GAAP net loss of $(0.8) billion and GAAP EPS of $(2.13) Updates 2025 ...

Merck & Co., Inc. (NYSE: MRK) is one of the best depressed stocks to buy in 2025. On August 2, the company completed the ...

Merck (MRK) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts ...

Impax Asset Management, an investment management company, released its “Impax US Sustainable Economy Fund” second-quarter 2025 investor letter. A copy of the letter can be downloaded here.